Alopecia Clinical Trial
Official title:
Placental Mesenchymal Stem Cells-derived Exosome for Hairloss
Many people suffer from alopecia, which is caused by hereditary factors, emotional stress, and psychiatric disorders. There are devastating physical and psychological consequences as a result. Exosomes are isolated from donated human amniotic mesenchymal stem cells and purified using specific processing. Exosomes are unique in that they are derived from stem cells and contain a wide range of growth factors. The latest generation of natural products for treating hair loss is exosomes.
Exosomes contain a variety of growth factors that are derived from stem cells. As they are so small, they can be hidden in the bloodstream and carry different types of proteins. The Wnt-β-catenin pathway is thought to play a major role in the pathogenesis of hair loss. The only FDA-approved medications for the treatment of hair loss are minoxidil (a vasodilator) and finasteride (a selective inhibitor of 5α reductase type II and III isoforms). However, these drugs have not been very perfect. Both have been associated with limited efficacy, duration of effect, and several significant side effects. Regenerative medicine using cell products is looking for a way to heal faster and less cost. Present research focus on Exosome efficacy on hairloss. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Active, not recruiting |
NCT04953416 -
Fractional Non-ablative Laser for the Treatment of Hair Loss
|
N/A | |
| Completed |
NCT01929330 -
Bioequivalence Study of Dutasteride Five 0.1 mg and One 0.5 mg Soft Gelatin Capsules in Healthy Male Volunteers
|
Phase 1 | |
| Recruiting |
NCT05213936 -
Scalp Cooling for Chemotherapy-Induced Alopecia in Patients of Color
|
N/A | |
| Completed |
NCT02919735 -
Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)
|
Phase 2 | |
| Recruiting |
NCT02591823 -
Hair Fall in Patients on Low Dose Methotrexate
|
N/A | |
| Enrolling by invitation |
NCT01651689 -
Hair Counts From Vertical and Horizontal Sections of Scalp Biopsy SPecimens in Thai Population With Alopecia
|
N/A | |
| Completed |
NCT01189279 -
Safety and Pharmacokinetics Study of New Formulation of Bimatoprost in Patients With Alopecia
|
Phase 1 | |
| Recruiting |
NCT01111981 -
Safety and Efficacy of Clobetasol Propionate 0.05% E Foam in Alopecia
|
Phase 4 | |
| Terminated |
NCT01385839 -
Efficacy of Hair Transplantation Compared With Hypodermic Needle Irritation in Alopecia Areata
|
N/A | |
| Active, not recruiting |
NCT03382184 -
Fractional Photothermolysis for Hair Follicle Induction
|
Early Phase 1 | |
| Not yet recruiting |
NCT05544448 -
In Vitro Effect Study of Interleukin-2 Muteins on Regulatory T Cells of Patients With Different Autoimmune, Allo-immune or Inflammatory Diseases
|
N/A | |
| Completed |
NCT03689452 -
The Effect of Platelet Rich Plasma on Non-scarring Alopecia
|
N/A | |
| Completed |
NCT06409650 -
To Evaluate Safety and Efficacy of KX-826 in Chinese Female Subjects With Androgenetic Alopecia
|
Phase 2 | |
| Recruiting |
NCT00801086 -
Efficacy Study of Tempol to Prevent Hair Loss From Radiotherapy to the Brain
|
Phase 2 | |
| Completed |
NCT06095739 -
Study to Investigate the Effectiveness of a Topical Cosmetic Formulation DA-OTC-002
|
N/A | |
| Completed |
NCT05587699 -
The Parallel Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of CKD-843 A
|
Phase 1 | |
| Completed |
NCT03351322 -
ENERGI-F701 for Female Hair Loss Treatment
|
Phase 2 | |
| Terminated |
NCT02935569 -
Compression Headband Use to Prevent Hair Loss During Whole Brain Radiotherapy
|
N/A | |
| Not yet recruiting |
NCT01557491 -
Hair Regrowth After Bicoronal Incision
|
N/A | |
| Completed |
NCT01590238 -
Enhancing Hair Density With Platelet Rich Fibrin Matrix (PRFM)
|
Phase 3 |